ZNF415 Inhibitors
Chemical inhibitors of ZNF415 function through diverse molecular pathways to alter the phosphorylation state and activity of this protein. Staurosporine, a potent protein kinase inhibitor, can inhibit a wide range of kinases that may phosphorylate ZNF415, thus preventing its activation or the ability to interact with specific substrates. Similarly, Wortmannin and LY294002, as PI3K inhibitors, can reduce the phosphorylation of downstream targets that are involved in regulating ZNF415's function. This decreases the overall functional activity of ZNF415 by limiting its interaction with other signaling molecules that are normally modified by the PI3K pathway. Another inhibitor, Rapamycin, targets the mTOR pathway, which is integral to cellular growth and proliferation. Inhibition of mTOR can lead to reduced activity of downstream effectors that might modulate ZNF415 function, altering the regulatory control that ZNF415 exerts within the cell.
Further, U0126 and PD98059 specifically inhibit MEK1/2 within the MAPK/ERK pathway, a pathway known to contribute to a variety of cellular functions. By blocking this signaling, these inhibitors can downregulate the activity of proteins that are crucial for ZNF415's functional activity. The JNK pathway inhibitor SP600125 and the p38 MAPK inhibitor SB203580 disrupt signaling that could be critical for ZNF415's activity, particularly if ZNF415 is modified by kinases in these pathways. Dasatinib, which targets the Src family kinases, can prevent the phosphorylation and subsequent activation of ZNF415 by inhibiting kinases that normally interact with or regulate ZNF415. Inhibitors such as H-89 and Chelerythrine, which are specific to PKA and PKC respectively, can decrease the phosphorylation and activity of proteins within their signaling pathways, thus potentially reducing ZNF415's activity if it is associated with these pathways. Lastly, Bortezomib, a proteasome inhibitor, can disrupt normal protein turnover and induce cellular stress, which can indirectly affect the stability and function of ZNF415 if it relies on proteasomal degradation for regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad spectrum of protein kinases, which may include kinases that phosphorylate ZNF415, therefore preventing its activation or interaction with specific substrates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which is involved in multiple signaling pathways. Inhibition of PI3K can reduce the phosphorylation of downstream targets that could be involved in regulating ZNF415's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin, which by inhibiting the PI3K pathway, can decrease the phosphorylation state of proteins that interact with or regulate ZNF415. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and proliferation. If ZNF415 is involved in these processes, mTOR inhibition can reduce the activity of downstream effectors that may regulate ZNF415 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 which is part of the MAPK/ERK pathway, a pathway known to regulate a wide range of cellular functions. Inhibition of this pathway can downregulate the activity of proteins that are crucial for the functional activity of ZNF415. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that could block the MAPK/ERK signaling, which may be necessary for the functional regulation of ZNF415, by reducing the phosphorylation of downstream targets involved in the regulation of ZNF415. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the JNK pathway, which, if involved in the regulation or activity of ZNF415, its inhibition could decrease the activity of ZNF415 by altering the phosphorylation of proteins that interact with ZNF415. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which by inhibiting p38 MAPK, can disrupt downstream signaling that may be critical for the activity of ZNF415, particularly if ZNF415 is phosphorylated by kinases in this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases can phosphorylate a range of substrates that could interact with or regulate ZNF415. Inhibiting these kinases can prevent the phosphorylation and subsequent activation of ZNF415. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a protein kinase C (PKC) inhibitor. PKC is involved in various cellular processes, including signal transduction pathways. Inhibition of PKC can result in decreased phosphorylation and activity of proteins that may regulate the function of ZNF415. | ||||||